CORNEA

Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury

Retrieved on: 
Wednesday, April 21, 2021
Branches of biology, Biology, Senescence, Neuregulin 1, Proteins, Regeneration

No one has yet found a method that leads to cardiovascular regeneration for a damaged human heart.

Key Points: 
  • No one has yet found a method that leads to cardiovascular regeneration for a damaged human heart.
  • "\nWhite\'s paper explains that neonatal cardiac repair is mediated by the epicardium, which is a single layer of cells that covers the heart.
  • Others can use this tool, apply their own specialties to further the knowledge of the mechanisms of cardiac regeneration to reduce the impact of heart diseases.
  • Neuregulin-1, in a Conducive Milieu with Wnt/BMP/Retinoic Acid, Prolongs the Epicardial-Mediated Cardiac Regeneration Capacity of Neonatal Heart Explants.

Nine Bascom Palmer doctors named to Power List Honoring Top Women in Ophthalmology

Retrieved on: 
Thursday, April 1, 2021
Healthcare in the United States, Health, Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Pediatric ophthalmology, Burton J. Kushner, Jane D. Kivlin

MIAMI, April 1, 2021 /PRNewswire/ --Nine esteemed ophthalmologists at Bascom Palmer Eye Institute were selected for The Ophthalmologist Power List 2021, which honors the world's 100 most influential women in the field of ophthalmology.

Key Points: 
  • MIAMI, April 1, 2021 /PRNewswire/ --Nine esteemed ophthalmologists at Bascom Palmer Eye Institute were selected for The Ophthalmologist Power List 2021, which honors the world's 100 most influential women in the field of ophthalmology.
  • She also devotes time to teach and support women in the field of ophthalmology and retina.
  • Holder of the John T. Flynn Chair in Ophthalmology, Dr. Hilda Capo is a specialist in pediatric ophthalmology and adult strabismus.
  • Bascom Palmer's faculty members have been well represented on the Power List since its inception in 2014.

BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition

Retrieved on: 
Wednesday, February 10, 2021
Anatomy, Medical specialties, Branches of biology, Urinary bladder disorders, Urinary system, Overactive bladder, Botulinum toxin, Urinary bladder, Detrusor muscle, Hyperhidrosis, Urology, Hyperkinesia

When caring for pediatric patients with neurogenic detrusor overactivity, we strive to reduce bladder pressure and increase the bladder's capacity.

Key Points: 
  • When caring for pediatric patients with neurogenic detrusor overactivity, we strive to reduce bladder pressure and increase the bladder's capacity.
  • Today, BOTOX is FDA-approved for 12 therapeutic indications, including Chronic Migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults, cervical dystonia, spasticity, severe underarm sweating (axillary hyperhidrosis), and pediatric detrusor overactivity associated with a neurologic condition.
  • Your doctor may monitor you for breathing problems during treatment with BOTOX for spasticity or for detrusor overactivity associated with a neurologic condition.
  • Autonomic dysreflexia associated with intradetrusor injections of BOTOX could occur in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy.

Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference

Retrieved on: 
Friday, January 15, 2021
Academic journals, Academic publishing, Articles, Education, Toxins, Abstract, Build, Neurotoxins

These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.

Key Points: 
  • These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.
  • "With over 30 years in the neurotoxin space, we are excited to further build on this heritage as part of AbbVie.
  • The abstracts are expected to be published online in a supplement of the journal Toxicon onJanuary 16, 2021 with open access for six months after the conference.
  • The TOXINS 2021 Virtual Poster Hall opens on January 16 and will remain open to conference attendees for 60 days post-conference.

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales

Retrieved on: 
Wednesday, January 13, 2021
Health, Medical devices, Surgery, Other Technology, Other Health, Pharmaceutical, Optical, Blindness, Glaucoma, Earnings call, Cornea, Articles, Economy

Preliminary and unaudited total net sales for the fourth quarter of 2020 are expected to be approximately $73 million, consisting of approximately $58 million in Glaucoma net sales and approximately $15 million in Corneal Health net sales.

Key Points: 
  • Preliminary and unaudited total net sales for the fourth quarter of 2020 are expected to be approximately $73 million, consisting of approximately $58 million in Glaucoma net sales and approximately $15 million in Corneal Health net sales.
  • Preliminary and unaudited total net sales for the full year of 2020 are expected to be approximately $225 million, consisting of approximately $179 million in Glaucoma net sales and approximately $46 million in Corneal Health net sales.
  • These preliminary and unaudited net sales results are subject to revision until the company provides its full financial and operating results in its upcoming earnings release and earnings call for the fourth quarter of 2020, which is expected to be in late February.
  • Further, the preliminary financial results for the companys fourth quarter 2020 included in this press release represent the most current information available to management.